Nicholas Wrigley was a writer and editor for CancerNetwork and the journal ONCOLOGY.
He is also a writer of fiction; his work has appeared in a local anthology, the Best Short Stories of Philadelphia, and elsewhere. He holds an MFA in Creative Writing from Temple University and spends most of his spare time reading books, writing books, playing video games, or sleeping. He has inexplicably strong opinions on Russian history, Star Wars, and pasta. He lives in Greater Philadelphia with his family and, more importantly, his two dogs.
Despite Improving Responses, Pembrolizumab/Olaparib Fails to Improve Survival in mCRPCSeptember 29th 2022
Results from the phase 3 KEYLYNK-010 study showed that treatment with pembrolizumab and olaparib did not result in a statistically significant improvement in survival despite yielding higher responses compared with novel hormonal agents in patients with previously treated prostate cancer.
Chiara Cremolini, MD, PhD, Assesses Panitumumab Plus Triplet vs Doublet Chemotherapy in RAS/BRAF Wild-Type Metastatic CRCSeptember 25th 2022
Chiara Cremolini, MD, PhD, discussed results from the phase 3 TRIPLETE study of triplet chemotherapy plus panitumumab in previously untreated patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer.
Doris K. Hansen, MD, Analyzes Real-World Experiences With Idecabtagene Vicleucel in Relapsed/Refractory Multiple MyelomaSeptember 23rd 2022
Doris K. Hansen, MD, discussed results of an efficacy analysis examining the BCMA-directed CAR T-cell therapy idecabtagene vicleucel in real-world treatment of patients with relapsed/refractory multiple myeloma.
First-Line Olaparib/Bevacizumab Maintenance Combo Approved in China for HRD+ Advanced Ovarian CancerSeptember 23rd 2022
Olaparib and bevacizumab has been approved in China as a frontline maintenance treatment for patients with advanced homologous recombination deficiency–positive ovarian cancer based on results from the phase 3 PAOLA-1 trial.
Charles M. Rudin, MD, PhD, Examines Tiragolumab Plus Atezolizumab in Untreated Extensive-Stage Small Cell Lung CancerSeptember 9th 2022
Charles M. Rudin, MD, PhD, discussed results of the phase 3 SKYSCRAPER-02 trial examining atezolizumab with carboplatin and etoposide with or without tiragolumab in untreated extensive-stage small cell lung cancer.
Neoadjuvant Chemo May Reduce Necessity of Invasive Surgeries in Early-Stage Rectal CancerSeptember 1st 2022
Three months of neoadjuvant chemotherapy may downstage early-stage rectal cancer and thereby reduce the need for total mesorectal excisions (TMEs), resulting in higher rates of organ preservation.
Christine Parseghian, MD, Examines Anti-EGFR Rechallenge With Panitumumab Plus/Minus Trametinib in Metastatic CRCAugust 31st 2022
Christine Parseghian, MD, discussed the effects of rechallenging patients with a prior response to EGFR inhibition with panitumumab plus or minus the MEK inhibitor trametinib in RAS/BRAF wildtype, microsatellite stable colorectal cancer.
Aditya Bardia, MD, MPH, Examines Final Data for Sacituzumab Govitecan Vs Physician’s Choice Therapy in Previously Treated, Metastatic TNBCAugust 26th 2022
Aditya Bardia, MD, MPH, discussed final results from the phase 3 ASCENT study evaluating sacituzumab govitecan vs physician’s choice of single-agent chemotherapy for patients with relapsed or refractory metastatic triple-negative breast cancer.
Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung CancerAugust 24th 2022
Health Canada approved nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer prior to surgery.